Massimo Cristofanilli, MD, FACP

Articles

Closing Remarks on Treating Patients with HR+ Breast Cancer

February 13th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

Treatment after Progression on CDK4/6 Inhibitors

February 6th 2023

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

The Role of Surgery in Breast Cancer

February 6th 2023

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

Overview of Treatment Options for Patients with Breast Cancer

January 30th 2023

Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.

Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer

January 30th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.

Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer

January 23rd 2023

Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.

Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer

January 23rd 2023

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer

January 16th 2023

Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.

HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification

January 16th 2023

Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.

HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts

July 27th 2022

Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.

Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

July 27th 2022

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents

July 20th 2022

Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.

Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy

July 20th 2022

Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.

Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC

July 13th 2022

Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.

HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors

July 13th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer

July 6th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors

July 6th 2022

Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.

MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

June 29th 2022

Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.

MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy

June 29th 2022

Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.

PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

June 22nd 2022

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.